Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.

Details

Serval ID
serval:BIB_10B37DDC0947
Type
Article: article from journal or magazin.
Collection
Publications
Title
Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.
Journal
British journal of cancer
Author(s)
Hall P.S., Hamilton P., Hulme C.T., Meads D.M., Jones H., Newsham A., Marti J., Smith A.F., Mason H., Velikova G., Ashley L., Wright P.
ISSN
1532-1827 (Electronic)
ISSN-L
0007-0920
Publication state
Published
Issued date
03/03/2015
Peer-reviewed
Oui
Volume
112
Number
5
Pages
948-956
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
The rising financial burden of cancer on health-care systems worldwide has led to the increased demand for evidence-based research on which to base reimbursement decisions. Economic evaluations are an integral component of this necessary research. Ascertainment of reliable health-care cost and quality-of-life estimates to inform such studies has historically been challenging, but recent advances in informatics in the United Kingdom provide new opportunities.
The costs of hospital care for breast, colorectal and prostate cancer disease-free survivors were calculated over 15 months from initial diagnosis of cancer using routinely collected data within a UK National Health Service (NHS) Hospital Trust. Costs were linked at patient level to patient-reported outcomes and registry-derived sociodemographic factors. Predictors of cost and the relationship between costs and patient-reported utility were examined.
The study population included 223 breast cancer patients, 145 colorectal and 104 prostate cancer patients. The mean 15-month cumulative health-care costs were £12 595 (95% CI £11 517-£13 722), £12 643 (£11 282-£14 102) and £3722 (£3263-£4208), per-patient respectively. The majority of costs occurred within the first 6 months from diagnosis. Clinical stage was the most important predictor of costs for all cancer types. EQ-5D score was predictive of costs in colorectal cancer but not in breast or prostate cancer.
It is now possible to evaluate health-care cost using routine NHS data sets. Such methods can be utilised in future retrospective and prospective studies to efficiently collect economic data.
Keywords
Adult, Aged, Aged, 80 and over, Breast Neoplasms/economics, Breast Neoplasms/mortality, Breast Neoplasms/therapy, Colorectal Neoplasms/economics, Colorectal Neoplasms/mortality, Colorectal Neoplasms/therapy, Databases, Factual, Female, Health Status, Hospital Costs, Humans, Male, Middle Aged, Prostatic Neoplasms/economics, Prostatic Neoplasms/metabolism, Prostatic Neoplasms/therapy, Survival Analysis, United Kingdom, Young Adult
Pubmed
Web of science
Open Access
Yes
Create date
26/09/2019 7:39
Last modification date
27/09/2019 5:26
Usage data